What Analysts Are Saying About Edwards Lifesciences Stock
Portfolio Pulse from Benzinga Insights
Analysts have recently updated their ratings and price targets for Edwards Lifesciences (NYSE:EW), showing a generally positive outlook. Over the last three months, 10 analysts offered diverse opinions, with recent updates indicating raised price targets and ratings ranging from 'Buy' to 'Neutral'. The average 12-month price target is now $96.00, up from $86.22, suggesting an 11.34% increase. Edwards Lifesciences, known for its medical devices for heart disease, shows strong financial performance with a solid revenue growth rate, impressive net margin, and ROE, alongside effective debt management.
April 11, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Edwards Lifesciences has received positive analyst ratings and raised price targets, reflecting a bullish outlook. Financial indicators such as revenue growth, net margin, ROE, and ROA are strong, supporting a positive short-term impact.
The consensus among analysts towards Edwards Lifesciences is increasingly positive, with raised price targets and ratings indicating confidence in the company's performance. Strong financial metrics such as revenue growth, net margin, and ROE further support the optimistic outlook, likely leading to a positive short-term impact on EW's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100